Research
Search
Close
YANG Quanjun
- Doctoral Supervisor, Chief Pharmacist
- Department: Pharmacy
- Research Area: Pharmacology
- Research Interests: Cancer metabolism and immunotherapy
- Contact: myotime@sjtu.edu.cn
- Chief Pharmacist, Department of Pharmacy, Shanghai Sixth People’s Hospital, 2024
- Deputy Chief Pharmacist, Department of Pharmacy, Shanghai Sixth People’s Hospital, 2020
- Assistant Research Scientist, Yale School of Medicine, 2018
- Visiting Research Scientist, Yale School of Medicine, 2018
- Pharmacist-in-Charge, Department of Pharmacy, Shanghai Sixth People’s Hospital, 2017
- Pharmacist, Department of Pharmacy, Shanghai Sixth People’s Hospital, 2015
- Preparatory pharmacist, Department of Pharmacy, Shanghai Sixth People’s Hospital, 2014
- PhD from Shanghai Jiao Tong University, 2011
- Chief Pharmacist, Department of Pharmacy, Shanghai Sixth People's Hospital
- Deputy group leader, Drug Development and Translation Group, Shanghai Pharmaceutical Society
- Deputy group leader, Professional Group of Anticancer Drug Management, Shanghai Hospital Association
- Ye, L., Park, J. J., Peng, L., Yang, Q., Chow, R. D., Dong, M. B., ... & Chen, S. (2022). A genome-scale gain-of-function CRISPR screen in CD8 T cells identifies proline metabolism as a means to enhance CAR-T therapy. Cell metabolism, 34(4), 595-614.
- Ye, L., Park, J. J., Dong, M. B., Yang, Q., Chow, R. D., Peng, L., ... & Chen, S. (2019). In vivo CRISPR screening in CD8 T cells with AAV–Sleeping Beauty hybrid vectors identifies membrane targets for improving immunotherapy for glioblastoma. Nature biotechnology, 37(11), 1302-1313.
- Yang, Q. J., Zhao, J. R., Hao, J., Li, B., Huo, Y., Han, Y. L., ... & Guo, C. (2018). Serum and urine metabolomics study reveals a distinct diagnostic model for cancer cachexia. Journal of cachexia, sarcopenia and muscle, 9(1), 71-85.
- Yang, Q., Hao, J., Chi, M., Wang, Y., **n, B., Huang, J., ... & Guo, C. (2022). Superior antitumor immunotherapy efficacy of kynureninase modified CAR-T cells through targeting kynurenine metabolism. Oncoimmunology, 11(1), 2055703.
- Renauer, P., Park, J. J., Bai, M., Acosta, A., Lee, W. H., Lin, G. H., ... & Chen, S. (2023). Immunogenetic metabolomics reveals key enzymes that modulate CAR T-cell metabolism and function. Cancer immunology research, 11(8), 1068-1084.
- Wang, Y., Sun, X., Yang, Q., & Guo, C. (2023). Cucurbitacin IIb attenuates cancer cachexia induced skeletal muscle atrophy by regulating the IL‐6/STAT3/FoxO signaling pathway. Phytotherapy Research, 37(8), 3380-3393.
- Chen, L., Yang, Q., Zhang, H., Wan, L., **n, B., Cao, Y., ... & Guo, C. (2020). Cryptotanshinone prevents muscle wasting in CT26-induced cancer cachexia through inhibiting STAT3 signaling pathway. Journal of ethnopharmacology, 260, 113066.
- Li, C., Yang, Q., & Zhang, L. (2024). Identification of putative allosteric inhibitors of BCKDK via virtual screening and biological evaluation. Journal of Enzyme Inhibition and Medicinal Chemistry, 39(1), 2290458.
- Chen L, Zhang H, Chi M, et al. Bckdk‐Mediated Branch Chain Amino Acid Metabolism Reprogramming Contributes to Muscle Atrophy during Cancer Cachexia[J]. Molecular Nutrition & Food Research, 2023: 2300577.
- Zhu, X., Hao, J., Zhang, H., Chi, M., Wang, Y., Huang, J., ... & Yang, Q. (2023). Oncometabolite D-2-hydroxyglutarate—dependent metabolic reprogramming induces skeletal muscle atrophy during cancer cachexia. Communications biology, 6(1), 977.
- [Guo Cheng, Yang Quanjun, Chen Linlin] (2023), “Application of A STAT3 inhibitor ”, ZL 20202010054496.6
- [Guo Cheng, Yang Quanjun, Zhang Hong] (2023), “Application of linalool in the preparation of drugs for the treatment of cancer cachexia ”, ZL 2020 1 0085317.5
